drugset / Trial / NCT05966688

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

NCT05966688

Phase 1 Completed 39 enrolled Spero Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the pharmacokinetics (PK) of SPR720, azithromycin, and ethambutol, administered separately and co-administered, in healthy adult participants.

Timeline

Start
2023-08-04
Primary completion
2024-01-30
Completion
2024-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg Oral
Subject Ethambutol Small molecule 800 mg Oral
Subject SPR720 Small molecule 1000 mg Oral

Indications

No indication recorded.